For 14 people with a hormone-driven form of high blood pressure, the effects of a 6–12-month course of treatment were still visible as long as two years after they stopped taking the drug. The small follow-up study, led by Queen Mary University of London, points to a possible shift in how doctors treat some cases: addressing the cause, not only lowering blood pressure for as long as medication continues.
The treatment, called extended aldosterone synthase inhibition, or EASI, targets excess production of aldosterone. This hormone can make the kidneys hold on to too much salt, which raises blood pressure. In primary aldosteronism, benign nodules in the adrenal glands produce too much of it. Researchers estimate that this condition accounts for 5% to 10% of high blood pressure cases.
Most current treatments manage blood pressure rather than remove its source. Until now, a cure for this condition has required surgery to remove an entire adrenal gland. EASI uses a newer class of drugs to block aldosterone production. Researchers wondered whether taking the drugs for a longer period might do more than control hormone levels while treatment was under way.
The study, published in the New England Journal of Medicine, followed 14 people treated at eight centers across the United States. Researchers reviewed routine measurements of blood pressure and hormone levels after treatment and compared them with readings from before EASI began. The main marker of excess aldosterone production remained 99% lower than before treatment. Blood pressure was, on average, 25 points lower, and almost a quarter of participants had normal blood pressure without taking any other medication.
The hormone levels and blood pressure recorded after treatment were similar to, or lower than, the levels during treatment. That suggests the improvement may last after people stop taking the drug. The results are especially notable because earlier studies of this class of drugs generally lasted only 6–12 weeks and measured outcomes while participants were still taking them. This study examined a longer course of treatment and later follow-up.
The idea grew from research over many years. In 2005, an experiment in mice found that removing the gene responsible for producing aldosterone synthase caused the aldosterone-making cells to disappear. Queen Mary researchers proposed that prolonged treatment with an aldosterone synthase inhibitor might have a similar effect in people. A first study of this drug class in people with primary aldosteronism was reported last year, also in the New England Journal of Medicine.
Morris Brown, the study’s lead author and a professor of endocrine hypertension at Queen Mary, urged caution because the follow-up was pragmatic and involved only 14 people. He said the findings had been predicted by earlier experiments, but longer follow-up would be needed before researchers could make a stronger claim. Brown also stressed that EASI is unlikely to help most people with high blood pressure.
The results offer a reason for hope, not yet a proven cure. If larger studies confirm that a finite course of EASI can lead to lasting remission, some people with primary aldosteronism may one day avoid both lifelong medication and surgery. For now, researchers must test whether the striking improvements seen in this small group hold up over time and in more patients.
